Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol | Zendy

G. A. Baryshnikov | Zendy; И.И. Степанова | Zendy; N. A. Kudryavtseva | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol

Author(s) -

G. A. Baryshnikov,

И.И. Степанова,

N. A. Kudryavtseva

Publication year - 2014

Publication title -

systemic hypertension

Language(s) - English

Resource type - Journals

eISSN - 2542-2189

pISSN - 2075-082X

DOI - 10.26442/sg29049

Subject(s) - metoprolol , medicine , pharmacodynamics , heart failure , pharmacology , adrenergic beta antagonists , adrenergic receptor , cardiology , pharmacokinetics , propranolol , receptor

This article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokinetic characteristics of metoprolol succinate retard with other beta-adrenoreceptor-blocking agents showed metoprolol succinate advantage over the short-term drugs for treatment of CHF. According to the results of randomised clinical trialswe determined high therapeutic efficacy and safety of metoprolol succinate retard.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research